Skip to content

Study · Animal study (in vivo) · rat · 2017

3 results

Kisspeptin-10 inhibits OHSS by suppressing VEGF secretion.

Zhai J, Liu J, Zhao S, Zhao H, Chen ZJ, Du Y, Li W

Reproduction (Cambridge, England)4 Jul 2017Cited by 28 (Europe PMC)

PMID28676533 (opens in a new tab)DOI10.1530/rep-17-0268 (opens in a new tab)PepBankPUB-28676533
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with ovarian hyperstimulation syndrome, injected Kp-10 inhibited the increase in vascular permeability in ovarian and lung tissue.

    In plain wordsIn rats with ovarian hyperstimulation syndrome, Kp-10 injection reduced the rise in vessel leakiness.

    Peptide
    Kisspeptin-10
    Outcome
    DecreaseVascular permeability in OHSS rats
    Study

    ratn: not reported in source

    OHSS rat model
    Comparator
    Untreated OHSS rats
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Injection of exogenous Kp-10 inhibited the increase of VP and VEGF while promoting the expression of Kiss1r in both the ovarian and lung tissue of OHSS rats.
    1 context sentence
    Summary · context
    The aim of the present study was to elucidate the effects of kisspeptin-10 (Kp-10) on ovarian hyperstimulation syndrome (OHSS) and its related mechanism in OHSS rat models, human umbilical vein endothelial cells (HUVECs) and human luteinized granulosa cells.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In rats with ovarian hyperstimulation syndrome, injected Kp-10 inhibited the increase in VEGF in ovarian and lung tissue.

    In plain wordsIn rats with ovarian hyperstimulation syndrome, Kp-10 injection reduced the rise in VEGF.

    Peptide
    Kisspeptin-10
    Outcome
    DecreaseVEGF in OHSS rats
    Study

    ratn: not reported in source

    OHSS rat model
    Comparator
    Untreated OHSS rats
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Injection of exogenous Kp-10 inhibited the increase of VP and VEGF while promoting the expression of Kiss1r in both the ovarian and lung tissue of OHSS rats.
    1 context sentence
    Summary · context
    The aim of the present study was to elucidate the effects of kisspeptin-10 (Kp-10) on ovarian hyperstimulation syndrome (OHSS) and its related mechanism in OHSS rat models, human umbilical vein endothelial cells (HUVECs) and human luteinized granulosa cells.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In rats with ovarian hyperstimulation syndrome, injected Kp-10 promoted Kiss1r expression in ovarian and lung tissue.

    In plain wordsIn rats with ovarian hyperstimulation syndrome, Kp-10 injection raised the level of its own receptor in tissue.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseKiss1r expression in OHSS rats
    Study

    ratn: not reported in source

    OHSS rat model
    Comparator
    Untreated OHSS rats
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Injection of exogenous Kp-10 inhibited the increase of VP and VEGF while promoting the expression of Kiss1r in both the ovarian and lung tissue of OHSS rats.
    1 context sentence
    Summary · context
    The aim of the present study was to elucidate the effects of kisspeptin-10 (Kp-10) on ovarian hyperstimulation syndrome (OHSS) and its related mechanism in OHSS rat models, human umbilical vein endothelial cells (HUVECs) and human luteinized granulosa cells.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.